Epidemiology Surveillance Program
Lebanese Ministry of Public Health
as on 18/07/2018
| Age group | Gender, N, 2015 | Gender, %, 2015 | ||||||
|---|---|---|---|---|---|---|---|---|
| M | F | U | T | M | F | U | T | |
| 0-4y | 0 | 1 | 0 | 1 | 0.0 | 0.7 | 0.0 | 0.1 |
| 5-9y | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 10-14y | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 15-19y | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 20-24y | 0 | 1 | 0 | 1 | 0.0 | 0.7 | 0.0 | 0.1 |
| 25-29y | 1 | 1 | 0 | 2 | 0.2 | 0.7 | 0.0 | 0.3 |
| 30-34y | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 35-39y | 5 | 2 | 0 | 7 | 0.8 | 1.4 | 0.0 | 0.9 |
| 40-44y | 17 | 3 | 0 | 20 | 2.7 | 2.1 | 0.0 | 2.6 |
| 45-49y | 20 | 6 | 0 | 26 | 3.2 | 4.2 | 0.0 | 3.4 |
| 50-54y | 40 | 11 | 0 | 51 | 6.3 | 7.7 | 0.0 | 6.6 |
| 55-59y | 77 | 15 | 0 | 92 | 12.2 | 10.6 | 0.0 | 11.9 |
| 60-64y | 96 | 22 | 0 | 118 | 15.2 | 15.5 | 0.0 | 15.2 |
| 65-69y | 90 | 19 | 0 | 109 | 14.2 | 13.4 | 0.0 | 14.1 |
| 70-74y | 83 | 14 | 0 | 97 | 13.1 | 9.9 | 0.0 | 12.5 |
| 75+y | 183 | 43 | 0 | 226 | 29.0 | 30.3 | 0.0 | 29.2 |
| Unsp. | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total | 632 | 142 | 0 | 774 | 100.0 | 100.0 | 0.0 | 100.0 |
|
LNCR Application Epidemiology Surveillance Program Lebanese Ministry of Public Health |
|
as on 18/07/2018
| Subsite | Gender, N, 2015 | Gender, %, 2015 | ||||||
|---|---|---|---|---|---|---|---|---|
| M | F | U | T | M | F | U | T | |
| Trigone of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Dome of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Lateral wall of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Anterior wall of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Posterior wall of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bladder neck | 1 | 2 | 0 | 3 | 0.2 | 1.4 | 0.0 | 0.4 |
| Ureteric orifice | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Urachus | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Overlapping lesion of bladder | 0 | 0 | 0 | 0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bladder NOS | 631 | 140 | 0 | 771 | 99.8 | 98.6 | 0.0 | 99.6 |
| Total | 632 | 142 | 0 | 774 | 100.0 | 100.0 | 0.0 | 100.0 |
|
LNCR Application Epidemiology Surveillance Program Lebanese Ministry of Public Health |
|
as on 18/07/2018
| Group | Sub-Group | N, 2015 | %, 2015 |
|---|---|---|---|
| CARCINOMAS | SQUAMOUS CELL CARCINOMAS | 8 | 1.0 |
| CARCINOMAS | TRANSITIONNEL CELL CARCINOMAS | 652 | 84.2 |
| CARCINOMAS | ADENOCARCINOMAS | 9 | 1.2 |
| CARCINOMAS | OTHER SPECIFIED CARCINOMAS | 4 | 0.5 |
| CARCINOMAS | UNSPECIFIED CARCINOMAS | 11 | 1.4 |
| SARCOMAS | SARCOMAS | 3 | 0.4 |
| OTHER SPECIFIED MALIGNANT TUMOURS | OTHER SPECIFIED MALIGNANT TUMOURS | 1 | 0.1 |
| UNSPECIFIED | UNSPECIFIED | 86 | 11.1 |
| Total | 774 | 100.0 | |
|
LNCR Application Epidemiology Surveillance Program Lebanese Ministry of Public Health |
|
as on 18/07/2018
| Age group | Year 2015 | ||
|---|---|---|---|
| Male | Female | Both | |
| 0-4y | 0.0 | 0.3 | 0.2 |
| 5-9y | 0.0 | 0.0 | 0.0 |
| 10-14y | 0.0 | 0.0 | 0.0 |
| 15-19y | 0.0 | 0.0 | 0.0 |
| 20-24y | 0.0 | 0.4 | 0.2 |
| 25-29y | 0.4 | 0.4 | 0.4 |
| 30-34y | 0.0 | 0.0 | 0.0 |
| 35-39y | 2.8 | 1.0 | 1.9 |
| 40-44y | 12.0 | 2.0 | 6.8 |
| 45-49y | 17.5 | 4.9 | 11.0 |
| 50-54y | 39.4 | 10.4 | 24.6 |
| 55-59y | 84.5 | 15.3 | 48.7 |
| 60-64y | 115.3 | 25.5 | 69.6 |
| 65-69y | 165.8 | 31.2 | 94.6 |
| 70-74y | 175.5 | 28.1 | 99.8 |
| 75+y | 288.7 | 71.3 | 182.7 |
| Crude Rate | 21.3 | 4.7 | 12.9 |
| Crude Rate CI INF | 19.6 | 3.9 | 12.0 |
| Crude Rate CI SUP | 23.0 | 5.5 | 13.8 |
| ASR | 26.2 | 5.7 | 15.9 |
| ASR CI INF | 24.1 | 4.7 | 14.8 |
| ASR CI SUP | 28.3 | 6.6 | 17.1 |
|
LNCR Application Epidemiology Surveillance Program Lebanese Ministry of Public Health |
|